November 3rd, 2014
Selections from Richard Lehman’s Literature Review: November 3rd
Richard Lehman, BM, BCh, MRCGP
This week’s topics include dual-antiplatelet treatment beyond one year after DES implantation, reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome, and more.
October 7th, 2013
Study Supports Loosening Guidelines for Surgery After Stent Implantation
Larry Husten, PHD
According to current guidelines, noncardiac surgery should be delayed for six weeks after bare-metal stent (BMS) implantation and for one year after drug-eluting stent (DES) implantation, though there is little good evidence to support these recommendations. Stent thrombosis caused by discontinuation of antiplatelet therapy in order to lower the risk of bleeding during surgery is the […]
October 14th, 2011
FDA Advisory Panel Recommends First DES For PAD
Larry Husten, PHD
The FDA Circulatory System Devices Panel voted 11-0 on Thursday to support the premarket approval application for the Zilver PTX drug-eluting stent, manufactured by Cook Medical. The self-expanding, paclitaxel-coated stent would be the first DES approved for use in peripheral arterial disease of the above-the-knee femoropopliteal arteries. Cook Medical press release
NEJM Journal Watch — Recent Cardiology Articles- Self-Expanding Supraannular Valve vs. Balloon-Expandable Valve in TAVR for Small Aortic Annulus
- A New TAVR Prosthesis for Aortic Regurgitation Shows Promise
- Aprocitentan, a Newly Approved Drug for Resistant Hypertension
- Preventive PCI of Vulnerable Plaques Linked to Fewer Cardiac Events
- News from the ACC Scientific Session 2024